Identification of Potential Serum Protein Biomarkers and Pathways for Pancreatic Cancer Cachexia Using an Aptamer-Based Discovery Platform
Authors:
- Ashok NarasimhanANAshok Narasimhan
- Safi ShahdaSSSafi Shahda
- Joshua K. KaysJKJoshua K. Kays
- Susan M. PerkinsSPSusan M. Perkins
- Lijun ChengLCLijun Cheng
- Katheryn N. H. SchlossKSKatheryn N. H. Schloss
- Daniel E. I. SchlossDSDaniel E. I. Schloss
- Leonidas G. KoniarisLKLeonidas G. Koniaris
- Teresa A. ZimmersTZTeresa A. Zimmers
Open Access
Abstract
Patients with pancreatic ductal adenocarcinoma (PDAC) suffer debilitating and deadly weight loss, known as cachexia. Development of therapies requires biomarkers to diagnose, and monitor cachexia; however, no such markers are in use. Via Somascan, we measured ~1300 plasma proteins in 30 patients with PDAC vs. 11 controls. We found 60 proteins specific to local PDAC, 46 to metastatic, and 67 to presence of >5% cancer weight loss (FC ≥ |1.5|, p ≤ 0.05). Six were common for cancer stage (Up: GDF15, TIMP1, IL1RL1; Down: CCL22, APP, CLEC1B). Four were common for local/cachexia (C1R, PRKCG, ELANE, SOST: all oppositely regulated) and four for metastatic/cachexia (SERPINA6, PDGFRA, PRSS2, PRSS1: all consistently changed), suggesting that stage and cachexia status might be molecularly separable. We found 71 proteins that correlated with cachexia severity via weight loss grade, weight loss, skeletal muscle index and radiodensity (r ≥ |0.50|, p ≤ 0.05), including some known cachexia mediators/markers (LEP, MSTN, ALB) as well as novel proteins (e.g., LYVE1, C7, F2). Pathway, correlation, and upstream regulator analyses identified known (e.g., IL6, proteosome, mitochondrial dysfunction) and novel (e.g., Wnt signaling, NK cells) mechanisms. Overall, this study affords a basis for validation and provides insights into the processes underpinning cancer cachexia.Keywords
Funding Information
- National Cancer Institute (R01-CA122596, R01-CA194593, P30-CA082709)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01-DK096167)
- Lustgarten Foundation (No number)
- Heroes Foundation (No number)
- Lilly Endowment (No number)
- IUPUI Signature Center for Pancreatic Cancer Research (No number)
This publication has 87 references indexed in Scilit:
- Targeting the Transforming Growth Factor-β Signaling in Cancer TherapyBiomolecules & Therapeutics, 2013
- Definition and classification of cancer cachexia: an international consensusThe Lancet Oncology, 2011
- Interleukin 6 as a Key Regulator of Muscle Mass during CachexiaExercise and Sport Sciences Reviews, 2010
- The relationship among acute-phase response proteins, cytokines and hormones in cachectic patients with colon cancerWorld Journal of Surgical Oncology, 2010
- Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexiaBiochemical and Biophysical Research Communications, 2010
- The role of cytokines in cancer cachexiaCurrent Opinion in Supportive & Palliative Care, 2009
- Pathophysiology of cancer cachexia: Much more than host–tumour interaction?Clinical Nutrition, 2007
- Estradiol replacement reverses ovariectomy-induced muscle contractile and myosin dysfunction in mature female miceJournal of Applied Physiology, 2007
- The ubiquitin–proteasome system and skeletal muscle wastingEssays in Biochemistry, 2005
- A nitric oxide synthase transgene ameliorates muscular dystrophy in mdx miceJournal of Cell Biology, 2001